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For thousands of years, silver (Ag) has been widely used for medicinal purposes due to its 
broad-spectrum antimicrobial properties. While medicinal silver usage declined with the advent of 
antibiotics, there has been a renewed interest in therapeutic silver coordination compounds to 
combat the spread of antibiotic resistance. N-heterocyclic carbenes (NHCs) are promising ligands 
for silver metallodrugs due to their wide structural variety that allows for tunability of the 
complex’s overall steric and electronic properties and previously established bioactivity against 
various pathogens and cancer cell lines. There is potential for efficacy against biofilms, a type of 
microbial growth pattern that is common among numerous pathogens. In order to explore the 
impact of the steric and electronic properties of certain NHC structural features on the overall 
activity against Streptococcus mutans, the etiological agent behind cavities, a series of five Ag(I)-
NHCs were synthesized over the course of three steps and characterized: [(IMes)AgCl] (1), 
[(IPr)AgCl] (2), [(IMesMe2)AgCl] (3), [(SIMes)AgCl] (4), [(IMes)AgCl] (5). Challenges occurred 
while synthesizing complex 3, IPr∙HCl (14), and IMesMe2∙HCl (15). Complex 1 will serve as the 
baseline that all other complexes will be compared to in future antibacterial studies. The 
diazabutadiene and imidazolium chloride precursors and Ag(I)-NHCs were synthesized with low 
to moderate yields. Based on the reaction mechanisms and literature protocols, increasing the 
amount of the catalytic reagents as well as optimization of the isolation and purification techniques 
should improve yields. Future work should focus on the syntheses of [(BMes)AgCl] (6) and [(6-
Mes)AgCl] (7) which were unable to be completed due to time constraints. Upon successful 
completion of the syntheses, all will be given to the Santiago lab (Rollins Dept. of Biology) where 













Medicinal Inorganic Chemistry: Overview & History  
While the majority of compounds used medicinally are organic-based (e.g. small organic 
molecules, biologics), inorganic and organometallic complexes also have clinical applications. 
Medicinal inorganic chemistry is the study of active metal ions, coordination complexes, or salts 
that can be introduced into a biological system for the purposes of disease therapy or diagnosis.1 
Though metals have been used for medicinal purposes since ancient times by various civilizations, 
medicinal inorganic chemistry, as a formal discipline, is relatively young, having only established 
itself within the last century.  
The foundations can, in part, be traced to back to Paul Ehrlich (1854-1915), the father of 
chemotherapy, who, among other accomplishments, developed salvarsan, an arsenic-based anti-
syphilitic mixture, widely considered to be one of the first therapeutic metallodrugs.1,2,3 The 
discovery of the anticancer activity of cisplatin (Platinol®) during the 1960s further cemented 
medicinal inorganic chemistry as a discipline.1 Following this serendipitous finding, the field grew 
rapidly with numerous metal complexes developed for two primary purposes: disease therapy and 
diagnosis in the form of single-photon emission computed tomography (SPECT) positron emission 
tomography (PET) tracers and magnetic resonance imaging (MRI) contrast agents.2 Therapeutic 
metallodrugs have been used to primarily combat ailments like rheumatoid arthritis (e.g. auranofin, 
Ridaura®; sodium aurothiomalate, Myocrisin®) and various cancers (e.g. carboplatin, 
Paraplatin®; porfimer sodium, Photofrin®). Radiopharmaceuticals such as Rb-82 chloride 
(Cardiogen-82®), Tc-99m bicisate (Neurolite®), and Tc-99m tilmanocept (ProstaScint®) have 
become diagnostic imagining mainstays.2 Today, numerous metallodrugs have been FDA-
approved with others currently in clinical trials or the earlier phases of drug discovery and 
development.2  
History of Silver in Medicine  
People have taken advantage of silver’s antimicrobial properties for medicinal purposes 
since Ancient Greece. Historically, silver has primarily been used as a water purificator, a topical 
agent for burn and wound care, and a general anti-infective agent against various ailments.4 The 
Greeks and other ancient peoples would often store water, wine, and other beverages in silver 
vessels to prevent spoilage; a practice that some historians theorize could have led to the adoption 
of silverware for eating utensils by the upper class. Later explorers and settlers during the Age of 
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Exploration and beyond would take advantage of this by leaving silver coins or utensils at the 
bottom of beverage containers.4 Today, silver is still found in water filters with both ionic and 
nanosilver being investigated for both a small- and large-scale potable water disinfection.5 
Thought to facilitate the healing process, silver was often a staple in the treatment and 
management of both wounds and burn injuries. Silver was primarily employed in the form of silver 
sutures, silver leaf and other silver-containing dressings during the 1800s.5 In the 20th century, 
silver nitrate solutions were commonly prescribed for burn care. The clinical success of silver 
nitrate and mafenide acetate (Sulfamylon®), a sulfur-based burn treatment, led to the development 
of the topical burn ointment, silver sulfadiazine (Silvadene®).6 Silver sulfadiazine and other silver-
based burn and wound treatments continue to have clinical relevance to this day.  
Regarding its use as a general anti-infective agent, for centuries, various silver compounds 
(e.g. silver salts, silver proteinates, silver arsphenamine, silver acetate) have been used to treat a 
wide range of maladies such as: conjunctivitis and other ophthalmic conditions, allergies, colds, 
gastroenteritis, gonorrhea, syphilis, mental illness, and even smoking.4 Following the advent of 
antibiotics, medicinal silver use largely declined.4 Colloidal silver, which has historically been 
used as a general bactericide, has largely fallen out of the medical community’s favor. However, 
it has been coopted by those in the alternative medicine movement as a general cure-all.4 The rise 
of antibiotic and multidrug resistance in bacteria within the last few decades has led to a renewed 
interest in silver as a potential alternative.7 In particular, silver (Ag) has shown promise as a 
potential therapeutic agent due to its broad-spectrum antimicrobial properties.4  
Chemical Properties and Biological Activity of Silver 
Chemical Properties, Bioavailability, and Toxicity 
Silver is a lustrous pale grey noble metal that can form three bioactive oxidation states 
(Ag+, Ag2+, and Ag3+) each capable of forming coordination complexes.8,9 While many metals play 
an integral role in many biological processes and biochemical pathways, noble metals like silver 
are not considered essential for life. However, their resistance to oxidation and corrosion makes 
them useful for a variety of purposes, including biomedical applications.10,11 
Silver can enter the body via absorption, ingestion, and inhalation followed by cellular 
uptake. The exact mechanism varies by cell type. Entry of silver into the human body usually 
occurs via trace contamination in food and water supplies or occupational exposure.4 While the 
majority of ingested silver is ultimately excreted out of the body via feces, as much as 10% is still 
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absorbed.4 Though solid silver is insoluble in aqueous solutions, ionization in the presence of an 
oxidant can release reactive silver cations. What happens to silver in the body is dependent on the 
mode of entry and the form it is in (i.e. solid, ionic, or nano) as different biological anions (e.g. 
chloride, nitrate, sulfate, acetate, oxalate), biomolecules (e.g. proteins, nucleic acids), and 
environments (e.g. pH, exposure to sunlight) can impact cationic silver’s solubility, thus reducing 
the amount of the bioreactive species.4  
All toxicities are dose-dependent: too low of a concentration will result in little or no effect, 
too high will lead to toxicity, with the optimum physiological response range lying between the 
two.13,14 Silver is especially toxic to lower organisms, termed the oligodynamic effect, killing 
bacteria and other microbes at very low concentrations.6 Additional studies have also shown that 
silver possesses cytotoxic properties.4 While cell destruction is harmful and can result in tissue and 
organ damage, there are times when this is advantageous. Silver’s cytotoxicity can be modulated 
via host-guest chemistry or other methods to kill cancerous cells or microbes while sparing healthy 
cells opening the doors to potential clinical applications.15,16 
Overall, silver is primarily non-toxic to humans. While humans can tolerate low doses of 
silver, repeated exposure over time can result in negative effects such as silver accumulation in 
tissues, particularly those of the reticuloendothelial organs.4,17 The most well-known side effect of 
silver overload in humans is argyria, a permanent skin discoloration that can be attributed to 
sunlight-induced reduction of ionic silver in the skin. The resulting nanoparticles can form 
insoluble sulfides and selenides, causing the skin to turn blue-grey. Argyria can be localized to one 
or more specific areas or spread all over due to the transport and deposition of silver throughout 
the body via the bloodstream.4 As the majority of cases of argyria are due to excessive long-term 
exposure, this should not discount the establishded benefit and further potential of silver in the 
clinic. If silver is to continue to play a role in the future of medicine, research must continue behind 
the mechanisms behind silver’s absorption, distribution, metabolism, and excretion (ADME) and 
toxicity in order to effectively and safely administer and deliver silver-based therapeutics. 
Silver’s Mechanism of Action 
The mechanism behind silver’s cytotoxic activity is multifaceted, dependent on cationic 
silver’s interactions with biomolecules and other cellular components. Positively charged Ag ions 
can react with both electron-rich functional groups (e.g. nitrogen, sulfur, and oxygen-containing 
moieties) and anions (e.g. PO4
3-, Cl-, carboxylates) within cells and the bloodstream to form stable 
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complexes, altering the shape and charge of the overall compound and impairing a biomolecule’s 
function.2,3,7 Occasionally, the bonds holding these Ag-biomolecule complexes together can break, 
generating silver-free radicals that cause intracellular damage that is compounded by the 
suppression of oxidative stress responses.8,18 Studies on Escherichia coli have shown that Ag 
cations inhibit the energy-producing reactions of cellular respiration by damaging enzymes 
involved in glycolysis and the citric acid cycle.16 Furthermore, they disrupt iron-sulfur clusters 
which play a key role in electron transfer during the final stage of cellular respiration.4 Silver 
cations can also damage cell membrane integrity and inhibit cell replication by chelating to 
embedded proteins and nucleotide bases, respectively, as well as impair ion and nutrient 
concentration gradients and exchange.4,8 In bacteria specifically, electrostatic interactions between 
silver cations and the anionic portions of the cell membrane have been shown to inhibit bacterial 
movement or rupture the membrane, resulting in the release of key metabolites and amino acids.8  
Furthermore, silver has been shown to trigger a stress response in bacteria, inhibiting growth, 
division, and metabolism, rendering them viable, but not culturable (VBNC).19 When a bacterium 
finally does succumb to silver, it can serve as a reservoir for Ag ions that, when released, kill more 
bacteria, resulting in a so-called “zombie” effect.20 Given the numerous mechanistic effects that 
need to be overcome, silver resistance is rare in nature. While some silver-resistance genes do 
exist, studies have found that bacterial silver resistance can be overcome with sufficiently high 
concentrations of silver.8 
Current and Developing Applications of Medicinal Silver 
Outside of the realm of wound and burn care, silver-treated or -coated indwelling medical 
devices, such as central venous lines, Foley catheters, and endotracheal tubes, have become 
popular due to their ability to prevent hospital-acquired infections (HAIs) and biofilm 
development.6 With regards to the future of medicinal silver, several different forms of silver are 
currently being explored by those developing novel therapeutics (Figure 1).4,7 For example, 
several studies involving silver clusters have shown their potential for a wide range of biomedical 
purposes from theranostics to drug delivery.21,22 A similar class of compounds, the silver metal 
organic frameworks (MOFs), have also been explored as potential antibacterial agents. Studies 
have indicated that AgMOFs behave similarly to the aforementioned “zombie” bacteria, acting as 




Figure 1. Classes of silver-based medicinal agents. I) Clusters. II) Metal organic frameworks. III) 
Nanoparticles. IV). Coordination complexes. Structures and figures adapted from RSC Advances. 
Royal Society of Chemistry. January 18, 2019, 2673–2702.; Phys. Chem. Chem. Phys. 2017, 19 
(29), 19360–19368.; Inorg. Chem. Commun. 2020, 112, 107733.; and Wikimedia Commons.24-27 
 
Much attention has been given to silver nanoparticles which have shown to be effective 
against a wide variety of pathogens and cancer cell lines. The use of AgNPs in medicine is not a 
new idea as colloidal silver is an aqueous suspension of nanosilver.4 Silver nanoparticles’ diversity 
in structure and composition make them suitable for a wide range of biomedical purposes, from 
theranostics to incorporation into biomaterials. According to the NIH, there are currently 28 
clinical trials that involve AgNPs.28 Of those 28, only 14 have been completed. The remainder are 
either still recruiting or not yet recruiting or have been withdrawn, terminated, or an unknown 
status. Four have either completed or are currently in Phase 4 clinical trials, meaning the AgNPs 
in question have already been FDA approved and are being studied to gain further insight into their 
safety safety, efficacy, or optimal use.29 These studies included: a central venous catheter that was 
impregnated with AgNPs (AgTive®), AgNP-containing skin wipes (Theraworx) and a bioceramic 
sealer, and a nanosilver combined CaOH intracanal medication to treat post-operative pain 
following failed root canals.30-33 Likewise, the majority of the trials listed involved either AgNPs 
incorporated into existing medical treatments, devices, or tools for oral/dental applications. More 
research needs to be done as studies have shown silver nanoparticle can accumulate within tissues 
and are toxic to various human cell lines.4 Currently, there have been two clinical trials assessing 
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the AgNP toxicity in humans in Phase 1 and Phases 1 and 2, respectively, that were both conducted 
by Munger and coworkers.34-36 After orally dosing study participants with AgNPs, various body 
samples and measurements were taken. Researchers did not find any clinically important changes 
in metabolic, hematologic, or urinalysis measurements, pulmonary reactive oxygen species and 
pro-inflammatory cytokine levels, or morphological changes in the lungs, heart or abdominal 
organs.36 While this is very promising, it was noted that more studies involving increased dosage 
and exposure length and other organ systems are needed to fully determine the toxicity threshold 
in humans.36 
Another promising alternative is silver-based metallodrugs or silver coordination 
complexes. As the case of cisplatin shows, the therapeutic potential of metallodrugs cannot be 
understated. While silver coordination complexes are commonly evaluated for their catalytic 
properties, more researchers have begun to recognize the untapped therapeutic potential and assess 
their bioactivity.17 Numerous silver complexes bearing various ligands have been screened against 
a wide variety of microbes (i.e. Gram-positive, Gram-negative, and antibiotic-resistant bacteria, 
fungi, and parasites) and have shown promising results.17 As will be elaborated on in the next 
section, the ligands coordinated to the central silver ion heavily influence the shape and properties 
of the overall complex.  
Metallodrugs and Rational Drug Design 
As previously mentioned, silver has three oxidation states: Ag+, Ag2+, and Ag3+; all of 
which can form coordination complexes.8,9 While silver(II) and silver(III) complexes display 
higher reactivity, they have the drawback of being less stable, and therefore less effective, while 
in-vivo due to their higher oxidation states.4,9 Regardless, the reactive part of all silver metallodrugs 
is the coordinated silver ion.4 As previously noted, silver ions can complex with many common 
biological functional groups. For a silver complex to be an effective drug, it needs to be more 
discriminative, targeting a specific site on protein or a specific DNA sequence.  
Rational drug design, or structure-based design, can trace its roots to Paul Ehrlich’s 
Zauberkugel Theorie or magic bullet concept. Zauberkugels are hypothetical agents that can 
effectively kill an invading pathogen without harming the body itself.3 According to rational drug 
design, structural data from a specific biomolecular target and/or biochemical ligand should be 
used to design and optimize potential lead compounds.37 Ideally, the lead should be as 
complementary as possible to the targeted binding site in both shape and charge to minimize off-
13 
 
target effects.2 Regarding silver metallodrugs, modularity in design allows for variability in both 
the type and number of ligands surrounding the central metal ion, resulting in numerous possible 
three-dimensional structures and electronic distributions that can be customized to each target 
binding site.2 Nevertheless, even if a drug was rationally designed, there is no way to predict 
precisely how the drug will react in-vivo.  
For metallodrugs specifically, a key concern is the possibility of ligand exchange or 
transmetalation with antitargets which, in the case of silver complexes, can cause premature silver 
ion release. However, these processes are less likely to occur if the silver complex is sufficiently 
stable. Specifically, the overall silver coordination complex must have a relatively high stability 
constant (β) to remain intact as it travels throughout the bloodstream to the intended target and 
interacts with various ligands. As such, the silver-ligand bonds within the complex must be 
sufficiently strong.2 Regarding metallodrugs, the steric and electronic properties of the ligand(s) 
coordinated to the central metal have a significant influence on the physiochemical properties of 
the metallodrug, dictating its pharmacokinetics and overall efficacy.2 While various types of 
ligands have been coordinated to silver, phosphines, those bearing nitrogenous heterocycles (e.g. 
phenanthrolines, pyridines, polypyridines), and current drug molecules (e.g. Metronidazole, 
Carbocysteine; coumarins) are the ligands that have shown the most promising results.4,17  
Currently, the Habgood lab, in conjunction with the Santiago lab (Rollins College Dept. of 
Biology), is exploring the efficacy of various silver compounds against Streptococcus mutans. As 
of now, six silver(I) salts bearing various cyanoximate ligands have been synthesized by the 
Habgood lab. The cyanoxime ligand family, characterized by C=NOH moieties, include both a 
cyano group (C≡N) and a variable R group bonded the imine carbon (Figure 2).38 
 
Figure 2. A generic silver(I) cyanoximate complex.  
 
The Santiago lab has started to screen these compounds against S. mutans, producing 
promising results. However, more research needs to be done on the stability of Ag(I) cyanoximates 
while in solution and the reactivity of the cyanoximate anion itself, especially since it bears a cyano 
group.39 There is the possibility that the cyano group could break off while in-vivo and cause 
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cyanide poisoning which would be problematic. Given their established biofilm activity, high 
stability, and steric and electronic tunability, silver(I) N-heterocyclic carbenes (NHCs), or Ag(I)-
NHCs, have the potential to be more effective against S. mutans. A previous study screened several 
pyrazine-functionalized Ag(I)-NHCs against S. mutans and found that their minimum inhibitory 
concentration (MIC) values ranged between 4-32 μg/mL (Figure 3).40 
 
 
Figure 3. Pyrazine-functionalized Ag(I)-NHCs previously screened against S. mutans. Adapted 
from Curr. Med. Chem. 2012, 19 (24), 4184–4193.40 
 
N-Heterocyclic Carbenes 
Structural and Electronic Properties 
Of the previously mentioned ligand families, N-heterocyclic carbenes (NHCs) are some of 
the most attractive. For a ligand to be an NHC, it needs to be a heterocycle (a ring system composed 
of at least two different elements) that contains a carbene carbon (a neutral, divalent carbon atom 
with two unshared valence electrons) and at least one nitrogen (Figure 4).41 General NHC 
structural features include: the nitrogen heteroatom(s) with bulky substituent(s) bonded to the 
nitrogen atoms and the size and composition of the ring backbone. The steric and electronic effects 
of these features help stabilize the carbene carbon and make it nucleophilic, allowing it to 
coordinate to transition metals, like silver, and form stable complexes.  
 
Figure 4. A generic silver-NHC complex. R and R’ may be identical or different, vary in size, 
and/or possess electron-donating or withdrawing groups.  
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In general, NHCs are classified as L-type ligands, meaning they are neutral Lewis bases 
that donate two electrons during the formation a coordinate covalent bond.42 They are considered 
strong σ-donor ligands, due to the high energy level of the highest occupied molecular orbital 
(HOMO).43 While there are several different methods to experimentally evaluate a given NHC’s 
donor-acceptor properties, the electronic variation between individual NHC ligands can be 
ascribed to differences in the backbones and R substituents. There are two main factors: the 
inductive effect (I) and the mesomeric or resonance effect (M/R). The inductive effect deals with 
the presence of electron-withdrawing (-I) or electron-releasing groups (+I), while the mesomeric 
effect is concerned with lone pair donating (+M) and withdrawing (-M) ability. The inductive and 
mesomeric properties of a given heteroatom or functional group can either increase the overall 
NHC electron density, improving its donor ability, or decrease it and make it a poor donor.43  
N-Heterocyclic Carbenes versus Phosphines 
Phosphines are another family of L-type ligands comprised of organophosphorus-based 
compounds. Their denticity can vary, with mono-, bi-, tri-, and tetradentate phosphines both 
commercially and synthetically available. The symmetry or lack thereof between the R groups 
attached to the phosphine atom can be used to broadly classify phosphines into three main classes: 
homoleptic (PR3), heteroleptic (R2PR’), and asymmetric or P-chiral phosphines (PRR’R’’) 
(Figure 5).44 The identity of said R groups can be used to modulate both the steric and electronic 
properties of the overall complex.44 Of the three classes, heteroleptic phosphines are the easiest to 
synthesize and tailor, opening the doors to a wide variety of purposes. Since their widespread 
adoption in during the mid to late 20th century, phosphines have established themselves as an 
important class of ligands when designing and synthesizing transition metal complexes, especially 
within the field of catalysis. 
 
 
Figure 5. Classes of phosphines. I) Homoleptic. II) Heteroleptic. III) Asymmetric. R, R’, and 
R’’’ can be Hs, alkyls, aryls, or other organic groups.  
 
Other applications beyond catalysis include inorganic/organometallic synthesis as well as 
materials, solid state, and medicinal chemistry.44 Indeed, silver phosphine complexes have been 
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explored as both potential antibacterial and anticancer agents, exhibiting activity against strains of 
E. coli, Salmonella typhimurium, and Staphylococcus aureus as well as various cancer cell lines.17 
Their anticancer activity can be attributed to both their interactions with DNA, with some 
derivatives exhibiting intercalation, and their lipophilicity. However, such a high lipophilicity 
presents aqueous solubility issues, making them unsuitable for environments like the bloodstream 
and mouth, thus necessitating the presence of more polar co-ligands to expand their usage beyond 
topical agents like ointments and creams.17 
 Compared to Ag-phosphines, Ag(I)-NHCs do not have those solubility issues with some 
Ag(I)-NHC complexes remaining stable in aqueous solution for up to 17 weeks due to the presence 
of electron-withdrawing groups on the central imidazole.17 Other studies have shown that NHC 
coordination compounds have higher thermal and oxidative stability than similar phosphine 
complexes making them more suitable for medicinal applications.41 This is because the high 
stability of Ag(I)-NHCs allows for sustained release of silver over time, which can be beneficial 
for both cancer treatment, stopping bacterial infections, and preventing reinfection from 
occurring.17 Furthermore, NHC-transition metal bonds are less prone to dissociation than 
phosphine-transition metal bonds. This makes Ag(I)-NHC complexes more likely to withstand 
travel through the bloodstream and arrive at their target without premature silver release, thus 
minimizing off-target effects.17,35  
The higher stability of Ag(I)-NHCs can be attributed to the electronic differences between 
these two families of ligands. While both are L-type ligands which donate a lone pair, phosphines 
possess a non-directional s-type lone pair whereas NHCs have highly directional sp2-type lone 
pairs, making NHCs stronger σ-donors.45 Additionally, while both ligands are σ-donors, 
phosphines are also π-acceptors allowing for π-backbonding interactions. As a result, metal-NHC 
bonds are more electron-rich than similar metal-phosphine bonds, making the metal-carbene 
carbon bond the stronger of the two.45 Regarding synthetic tractability, when the first NHC 
synthesis was reported by the Arduengo group, NHCs were largely considered to be less 
convenient phosphine alternatives as they were not commercially available and difficult to 
synthesize. Following the discovery of the catalytic activity of NHC-transition metal complexes, 
NHCs have become more widely adopted with numerous synthetic routes published and 
optimized, making these ligands relatively straightforward to synthesize if they are not 
commercially available.46 All of these factors combined with the structural versatility that allows 
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one to tailor both the sterics and electronics make NHCs good ligands for silver-based 
metallodrugs.   
Silver(I) N-Heterocyclic Carbene Complexes: Ag(I)-NHCs 
Bioactivity of Ag(I)-NHCs 
Numerous studies have been conducted on silver-NHC complexes, evaluating both their 
anticancer and antimicrobial properties. Although cisplatin and other platinum(II)-based 
metallodrugs have been traditionally used as chemotherapeutics, the numerous adverse effects 
associated with platinum(II) drugs as well as both inherent and acquired platinum resistance has 
generated a pressing need for less toxic and more effective anticancer agents.47,48 Various Ag(I)-
NHCs have been tested against a wide range cancer cell lines, such as OVCAR-3 (ovarian), HCT8 
(colon), UKF-NB-3 (neuroblastoma), A549 and A549R (normal and cisplatin-resistant lung), and 
more.49 While cytotoxicity varies and is dependent on both the complex structure as well as the 
cancer cell line, in general, Ag(I)-NHCs display comparable or improved activity compared with 
cisplatin and other standard anticancer chemotherapeutics. Overall, Ag(I)-NHCs have been found, 
among other things, to inhibit cancer cell growth, restore apoptosis, and decrease tumor mass with 
low cytotoxicity toward noncancerous cells.4,49,50  
Regarding Ag(I)-NHCs’ antibacterial activity, numerous studies have shown effectiveness 
against both Gram-positive and Gram-negative bacteria.49 Even more promising is their activity 
against antibiotic resistant strains of S. aureus, Pseudomonas aeruginosa, and  Burkholderia 
cepacia.49 Furthermore, Ag(I)-NHCs, especially ones possessing aromatic NHCs, are active 
against biofilms, which are inherently antimicrobial-resistant.4,51 Biofilms are a growth pattern in 
which bacteria or other microbes aggregate together and generate an extracellular polymeric 
substance matrix that acts as a protective barrier.51  
Biomedical Applications of Ag(I)-NHCs 
Biofilms are especially problematic since they grow on a variety of surfaces including those 
of medical devices. The majority of nosocomial infections are due to biofilm growth on an 
implanted medical device.52 This often results in device failure and necessitates its removal to treat 
the subsequent infection. To combat this potentially deadly problem, various antimicrobial 
coatings (AMCs) have been developed to prevent biofilm growth. AMCs fall under two categories: 
antibiotic-eluting device coatings and non-drug eluting coatings, which include metallic (e.g. 
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silver-based) coatings.53 Due to their antibiofilm activity, Ag(I)-NHCs could potentially be 
incorporated within AMCs, possibly acting as a hybrid of the two main types.  
Not even our own mouths are spared from biofilm intrusion. Over hundreds of different 
species of bacteria reside within the oral cavity. Dental plaque occurs when these metabolically 
active microbes colonize and anchor on to the surfaces of our teeth.54 Bacterial metabolism results 
in several changes to the surrounding environment, resulting in the degradation of the outer layers 
of dental tissue which, if left untreated, results in cavities. The main culprit behind dental caries is 
the Gram-positive bacterium, Streptococcus mutans. The etiology of dental caries can be attributed 
to S. mutans irreversibly binding to teeth and producing high concentrations of glucans (a 
polysaccharide) and lactic acid, resulting in the dissolution of the hydroxyapatite crystals 
[Ca5(PO4)3(OH)] that strengthen enamel and dentin.
54 Given the high incidence and widespread 
distribution of dental caries, there is a vested interest in finding ways to combat S. mutans. 
Specific Aims 
Overview 
In order to determine how ligand sterics and electronics affect the strength of the Ag-C 
bond and the overall antibacterial activity of the complex, a series of seven Ag(I)-NHC complexes 
coordinated to different NHCs were originally selected to synthesize with the complex, 
[IMesAgCl], (1) acting as the baseline against which all other complexes will be compared. Of the 
seven proposed compounds, only five were successfully synthesized (Figure 6).  
 
Figure 6. Target ligands and baseline Ag(I)-NHC complex, 1.  
 
While all the ligands have different electronic environments, the primary electronic factor 
chosen for investigation was the impact the of the backbone double bond. Of the five synthesized 
compounds, three were coordinated to ligands (IMes, IPr, and IMesMe2) that possessed at least one 
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pair of pi backbone electrons, while the remainder (SIMes and SIPr) had saturated heterocycles. 
The distinguishing factor between electronically similar ligands are the steric properties. Ligands 
differ due to alterations to the nitrogenous substituents as is the case for IMes and IPr and SIMes 
and SIPr. For those ligands, the nitrogens can either be attached to mesitylene groups or more 
sterically hindered diisopropylphenyls. The remaining NHC, IMesMe2, has increased steric bulk 
due to the addition of methyls directly to the backbone.  
Outline of Experimental Work 
 The complexes, [Ag(IMes)Cl] (1), [Ag(IPr)Cl] (2), [Ag(IMesMe2)Cl] (3), are to be 
synthesized over the course of a three-step synthetic route based on the literature (Scheme 1).46, 55-
60 Diazabutadiene precursors (8-10) are first prepared via a condensation reaction wherein 
arylamines undergo a condensation reaction with either glyoxal or diacetyl. After which, an 
electrocyclization reaction would be used to generate imidazolium chlorides (13-15).46,55,56,58,59 
The imidazolium salts are then coordinated to silver using Lin’s method to generate 1-3.57 
Complexes, [Ag(SIMes)Cl] (4) and [Ag(SIPr)Cl] (5), will bypass the first two steps of that reaction 
pathway by coordinating commercially-available salts, 16 and 17, to the silver.60 Following the 
completion of the syntheses of the target molecules, both the Ag(I)-NHC complexes and NHC 
salts will be given to the Santiago lab to be screened against S. mutans. The results generated from 














Results and Discussion 
Target complexes 1-5 and their precursors (8-10, 13-15) were successfully synthesized using 
published procedures with low to moderate yields (Scheme 1). 55-60 Compounds were characterized 
via 1H NMR and spectra were compared to previously reported NMR data to confirm identity.55-
62 
 
Scheme 1. Synthesis of 1-5, 8-10, and 13-15.55-60 
 
Syntheses of Diazabutadienes  
Compounds 8-10 were all synthesized using the same method: two arylamines (i.e. 2,4,6-
trimethylaniline or 2,6-diisopropylaniline) undergo successive condensations reactions with a 
dicarbonyl compound (i.e. glyoxal or 2,3-butanedione) to generate the corresponding diimine or 
diazabutadiene.46 All three diazabutadienes were successfully synthesized with moderate yields 
that were lower than the reported yields: 71% (Lit.= 85-95%), 64% (Lit.=80-90%), and 57% (Lit. 
= 68%) for 8, 9, and 10, respectively.55,58 This could be due to the fact that the condensation 
reaction is reversible and that the reverse reaction, imine hydrolysis, could be occurring, thus 
regenerating the starting material and resulting in lower yields.46 Because this reaction is acid-
catalyzed, having an insufficient amount of catalyst present within the system could limit the 
amount of product generated within a given period the catalyst may get saturated, thus forcing 
some reactants to undergo condensation at the slower, uncatalyzed rate. Finally, excessive washing 
of the isolated product could result in loss of yield. 
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Syntheses of Imidazolium Chlorides 
Of the three imidazolium salts that were synthesized, IPr∙HCl (14) and IMesMe2∙HCl (15) required 
multiple attempts. The first attempt at synthesizing 14 involved a procedure from the Nolan 
group.55 However, the resulting 1H NMR data differed from their reported results, indicating 14 
was not successfully synthesized. Another attempt was made using the same protocol that was 
adapted to have a longer heating time (65 hr vs the original 1 hr) at a lower temperature. However, 
the reaction dried out and attempts to salvage the reaction through the addition of more solvent 
failed.  
Further research revealed additional methods to synthesize 14 from the Jones group and 
Lamaty, Bantreil, Métro and coworkers.56,58 The reaction conditions reported by Lamaty and 
coworkers differed significantly from the previous attempts: the solvent was changed from ethyl 
acetate to THF and the reaction mixture was heated at a lower temperature over the course of 
several days.55,58 After heating the solution for six days, no color change had occurred and the 
resulting work-up yielded almost no product. No attempts at characterization were made since as 
there was insufficient material to prepare an 1H NMR sample. Compared to the Nolan protocol, 
the Jones procedure did not require heat and had additional steps for the work-up beyond washing 
with ethyl acetate.55,56 1H NMR spectra analysis indicated 14 was successfully made using the 
Jones protocol with a moderate yield (53%). Later examination of the 1H NMR data from the first 
attempt at synthesizing 14 found that, while the data did not match what the Nolan group reported, 
they did match the peaks reported by the Jones group.55,56 Further analysis is required to determine 
the identity of the sample as there are two impurities at 4.70 ppm (s, 1H) and 3.69 ppm (s, 1H) that 
cannot be accounted for. If the impurities were not part of the reaction solvent, it may still be 
possible to eliminate them using the Jones work-up.56 
Likewise, imidazolium chloride 15 required multiple attempts to synthesize. Originally, 15 
was to be synthesized using a protocol from the Lamaty group. However, given the significantly 
low yields that occurred while using their protocol to make 14, a protocol from the Louie 
laboratory was used instead.58,59 Difficulties were encountered during the isolation process 
following the bicarbonate wash since concentrating the reaction mixture in vacuo generated an 
oily residue. However, trituration with pentane afforded crude 15 with a low yield (34%). Attempts 
at obtaining pure 15 via recrystallization failed. Slow diffusion failed to produce any solid while 
standard multi-solvent recrystallization generated a white powder. However, the absence of all 
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reported 1H NMR peaks indicated it was not 15.59 A different purification protocol for 14 from the 
Lamaty group was found to eliminate the color from the crude 15, generating a white powder.58 
However, analysis did not indicate any significant difference between the 1H NMR spectra of the 
crude 15 pre- and post-work up. 
A second batch of 15 was made following failed attempts to synthesize complex 3 using 
crude 15. For this reaction, a new bottle of 4 M HCl in dioxane was used. Compared to the first 
attempt, this reaction’s progression appeared more promising since, after the addition of the 
paraformaldehyde-HCl solution, the solution turned the desired color (red), and not blood orange 
like the first attempt.59 Unlike the first attempt, the resulting precipitate from that reaction was 
terracotta brown rather than light brown. Greater care was taken during the second attempt to 
ensure that the precipitate was as clean as possible prior to the bicarbonate wash to avoid the 
purification issues from the last attempt. Approximately 2.5 L of diethyl ether was initially used 
to wash the compound. However, visual inspection of the filtrate indicated that the precipitate was 
not fully clean. As such, the precipitate was stored in 100 mL diethyl ether and allowed to stir for 
18 days. The long wash time had some impact as the isolated solid became light brown. During 
this attempt, trituration with pentane yielded both brown granules and a brown solid. However, 
NMR analysis indicated that the granules were impurities and were thus discarded. Using the 
Lamaty purification protocol again was found to successfully afford pure 15 with a 16% yield.58 
 The differences in appearances observed between the first and second attempts at 
synthesizing 15 suggest that the 4 M HCl in dioxane originally used during the first attempt at 15 
might not have been the correct molarity due to its age as the bottle was obtained in June of 2017. 
This is further supported by the increased yield during later attempts at synthesizing 13 and 14. 
Prior to the change in the reagent, the highest yield obtained for 13 was 37% and 53% for 14. After 
switching, yields increased to 90% and 70% for 13 and 14, respectively. During these later 
attempts, the paraformaldehyde-HCl solutions were observed to have a different appearance. The 
solutions appeared pale amber compared to the cloudy white solutions with visible particles of 
undissolved paraformaldehyde from the first attempts.  
The discrepancies in visual appearance and yields between the early and later attempts can 
be explained by the reaction mechanism. All imidazolium chloride salts were synthesized from the 
diazabutadiene precursors by way of a sigmatropic reaction in which paraformaldehyde was 
introduced as the C1 precarbenic unit (Scheme 2).
46 Prior to its addition to the diazabutadiene 
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solution, the paraformaldehyde must be dissolved in 4 M HCl in dioxane. This not only provides 
a source for the chloride counterions, but it allows for the in-situ generation of formaldehyde. Once 
the two solutions are combined, the formaldehyde is susceptible to nucleophilic attack from the 
diazabutadiene, resulting in a 1,5-dipolar cyclization at the end of which forms an imidazole 
wherein the formaldehyde carbon is now the carbene carbon.46  
 
Scheme 2. Imidazolium chloride formation mechanism. Formaldehyde is generated in situ via the 
depolymerization of paraformaldehyde in an earlier step. Scheme adapted from César et al. Chem. 
Rev. April 13, 2011, 2705–2733.46 
 
Previous literature has shown that in aqueous solution, the depolymerization of 
paraformaldehyde can be catalyzed by the presence of a base, an acid, or heat.63 Since the 
depolymerization reaction is endothermic, the addition of heat can often increase the rate with 
organic solvents, like dioxane, acting as a heat transfer media.64 During the first attempts at 
synthesizing 13-15, it is likely that there was insufficient HCl available to catalyze the 
depolymerization of paraformaldehyde due to the decrease in the reagent’s concentration overtime. 
As a result, the maximal yields for those reactions were greatly restricted, dependent upon the 
amount of formaldehyde was generated in situ rather than the amount of diazabutadiene.  
Syntheses of Ag(I)-NHCs 
The only silver-NHC complex that required multiple attempts to synthesize was [(IMesMe2)AgCl] 
(3). A review of the literature found only one reported synthesis of 3 by Lamaty and coworkers.58 
However, their protocol involved non-standard synthetic techniques and relied upon the use of 
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mechanochemical methods (i.e. vibratory ball-milling). Because of this, the synthetic protocols for 
1, 2, 4, 5 were used as guidance to design the synthesis of 3.58,60 At the time, attempts at purifying 
the complex’s corresponding salt, 15, had failed so crude 15 was used in the synthesis of complex 
3, under the assumption that the impurities present could be separated during the recrystallization 
process. For the crude complexation reaction, the reaction mixture stirred at RT for 24 hr under 
nitrogen. Following this, half of the solution was taken out of the glovebox, while the remaining 
half remained under nitrogen and was refluxed for a total of 12 hr. Both solutions were isolated 
using the same methods as 1, 2, 4, 5 and were recrystallized with pentane at 0°C.58.60 After a week, 
the black solutions and the black flakes that recrystallized out were characterized via 1H NMR. 
Spectra analysis indicated no significant difference between the refluxed and non-refluxed 
samples. The 1H NMR spectra of both solids indicated incomplete complexation, as both peaks 
from the starting material and the reported peaks of 3 were present and overlapping.58  
Based on those results, 1H NMR was used to monitor the complexation of 15 to silver in 
dichloromethane-d2 during the next attempt at synthesizing 3 (A1). For the complexation study, 
purified 15 was able to be used. The resulting 1H NMR indicated that after 14 hrs peaks at 9.86, 
7.13, 2.39, 2.10, 2.06, and 1.74 ppm disappeared (A1). Based on the reported 1H NMR peaks of 3 
and 15, the peaks at 7.13, 2.39, 2.10, 2.06, and 1.74 ppm likely do not correspond to the reactants 
or products and indicate impurities present within the initial reaction mixture.58 However, the 
disappearance of a miniscule peak at approximately 9.86 ppm suggests that the carbene H is no 
longer present, indicating that complexation did occur.58 However, 1H NMR analysis indicated 
that both 3 and 15 were likely still both present within the reaction mixture. Because of the identical 
splitting patterns and integrations as well as the closeness of the reported chemical shifts of 3 and 
15, it was difficult to conclusively determine if the complexation was successful.58 As a result, the 
complexation reaction was scaled up to obtain a more definitive result. For that reaction, pure 15 
and Ag2O were dissolved in DCM and the reaction mixture was heated to approximately 40°C and 
allowed to stir at 94.5 hr followed by a 70.5 hr RT stir. Again, the solution was isolated using the 
same methods as 1, 2, 4, 5 and recrystallized from DCM with pentane at 0°C. NMR analysis 
indicated that complex 3 was successfully synthesized with a percent yield of 46%. While this 
protocol resulted in a lower yield than Lamaty and coworkers (Lit. = 81%), it bypasses the need 
for a stainless-steel vibratory ball mill.58 
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 Complexes 4 and 5 were successfully synthesized with yields that were consistent with 
those reported in the literature: 77% (Lit.= 71%) and 63% (Lit.= 74%) for 4 and 5 respectively.60 
Complexes 1 and 2 were successfully synthesized with yields of 43% and 22%, respectively, using 
a protocol from the Vasam group.57 Unfortunately, they did not report their yields for 1 and 2. 
However, a search of the literature found that reactions with using the same reagents reported 
yields of 62% and 88% for 1 and 2, respectively.60,61 Discrepancies between yields could be 
explained by examining both the reaction mechanism and the protocol conditions.  
All five complexes were synthesized via Lin’s method, which is the most common method 
of synthesizing Ag(I)-NHCs since the reaction can be easily monitored, tolerates oxygen and a 
wide variety of solvents and solvent mixtures, and does not require solvent pretreatments or 
additional base.65,66 Lin’s method is dependent on the deprotonation of the NHC by the silver base, 
A2O. While there are other methods that use different silver bases (e.g. AgOAc, Ag2CO3), Lin’s 
A2O method has been shown to be more efficient than those involving other salts, requiring shorter 
times for similar reactions, which has been attributed to the higher basicity of A2O.
65,67 
Theoretical studies involving Density Functional Theory (DFT) calculations by the Lledós 
group have been used to provide mechanistic insight as to why this is the case.67 Basing their 
studies on the reaction between Ag2O and 1,3-dimethylimidazolium iodide in DCM, researchers 
proposed four possible mechanisms and determined which route was thermodynamically favored 
from the results of the DFT calculations. They concluded that the mechanism was a combination 
of two different routes: the sequential monomer pathway and the sequential dimer pathway 
(Schemes 3 and 4). The overall reaction is a thermodynamically driven process (ΔGrxn = -72.9 
kcal/mol) involving two imidazolium salts and Ag2O interacting over a series of very low barrier 
steps (Figures 7 and 8).67 
The first stage follows the sequential dimer pathway wherein the first NHC salt undergoes 
a barrierless and exergonic deprotonation by Ag2O (ΔG = -38.9 kcal/mol) followed by a low barrier 
exergonic metalation (ΔG = -35.0 kcal/mol) (Scheme 3; Figure 7).
67 The reaction is driven 
forward first by the relative acid-base strength of the imidazolium proton and Ag2O, then by the 
stabilization of the carbene following the formation of the Ag-C bond. Throughout the process, 
the second NHC stabilizes both the intermediates (A and C) and the transition state (B) by 
hydrogen bonding to silver oxide’s oxygen, making the reaction even more thermodynamically 
favorable. This results in approximately a 10 kcal/mol difference between the energy levels of the 
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intermediates and transition states of sequential dimer and sequential monomer pathways during 
the first deprotonation and metalation steps.67  
 




Figure 7. Gibbs free energy profile of the sequential dimer pathway in DCM.67 
 
After, the synthesized Ag(I)-NHC complex dissociates from the second NHC salt 
(Intermediate C), forming Intermediate M (ΔG = -59.6 kcal/mol) (Schemes 3 and 4). Once that 
occurs, the second NHC undergoes the deprotonation-metalation that occurs in the sequential 
monomer pathway (Scheme 4; Figure 8). The second deprotonation is slightly endergonic (ΔG = 
-58.1 kcal/mol) as the second imidazolium reacts with AgOH, which is a weaker base than Ag2O. 
While the second deprotonation has a slightly higher energy barrier and is less exergonic than the 




Scheme 4. Ag(I)-NHC formation via the sequential monomer mechanism.67 
 
 




There are several mechanistic reasons that could result in lower yield. Since DCM is a 
coordinating solvent and has been shown to form complexes with silver, it is possible that it could 
chelate to Ag2O, thus reducing its basicity.
67,68 However, the Lledós group concluded that the 
deprotonation of the imidazolium salt is significantly more favored, and that solvent coordination 
would not substantially impede the reaction.67 Another issue could be the structure of the NHC salt 
as functional groups that decrease the acidity of the imidazolium H have been shown to have 
reduced reactivity toward Ag2O and other silver bases.
65 Likewise, significant steric bulk around 
imidazolium H can also prevent deprotonation in which case reactions involving sterically 
hindered NHCs tend to require refluxing.65 The Vasam group’s protocol for 1 and 2 did not require 
refluxing and instead ran at room temperature for 18 hr.57 Of the remaining three compounds, only 
3 and 5 were refluxed. While 5 did have the highest yield, the protocol for 4 did not involve 
refluxing and resulted in a yield that exceeded the literature yield.60 A search of the literature shows 
that both 1 and 2 can be made either at room temperature or with a refluxing step.60,61,69,70 As such, 
it seems unlikely that the lack of the refluxing step can account for the discrepancy in yields. 
Numerous reports have shown that the halide counterion, solvent, and silver: NHC salt ratio can 
influence the solid-state structure of the resulting Ag(I)-NHCs (Figure 9).66 However, in general, 
N,N’-diaryl substituted imidazolium salts tend to only produce Type 2 complexes when reacting 
with Ag2O in DCM.
66 
 
Figure 9. Possible Ag(I)-NHC solid state structures.66 
 
 However, the most likely reason for the yield discrepancy is the loss of product during the 
recrystallization process. Complexes 4 and 5 have the highest yields of the five complexes and had 
different recrystallization or purification protocols from the others. Complex 4 was cooled to 0°C 
before a slow addition of heptane, resulting in the formation of the crude Ag(I)-NHC that was 
washed with pentane and dried under vacuum.60 Meanwhile, 5 was precipitated out of solution via 
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the addition of pentane and was subsequently washed with more pentane and dried under 
vacuum.60 The first three complexes followed a similar recrystallization process. All were 
concentrated in vacuo, redissolved in either THF (1 and 2) or DCM (3), and had aliquots of 
nonpolar solvent (hexanes for 1 and 2, pentane for 3) added over the course of several days and 
weeks during which the crystallization solutions were stored in a 0°C freezer. For complexes 1-3, 
it is likely that there was remaining product in the mother liquor that was not recovered, thus 
explaining the low yields. One possible remedy is to optimize the recrystallization protocol by 
either going slower and adding smaller aliquots of the nonpolar solvent or by utilizing different 
solvent pairs.  
 
Future Directions 
Two more Ag(I)-NHC complexes, 6 and 7, were originally proposed, but were unable to be 
successfully synthesized due to time constraints as generating sufficient amounts of complexes 1-
5 for the antibacterial studies was prioritized. Upon successful completion of the syntheses, all 
complexes will be given to the Santiago lab to be screened against S. mutans. The results generated 
from the Santiago lab will inform our choice of structural features for the next series of compounds. 
Regarding 6 and 7, both complexes have increased steric bulk compared to the baseline, 1, 
due to the addition of an aromatic benzene group (i.e. BMes) directly to the backbone (6) or the 
replacement of the central imidazoline with a 6-membered diazinane (7). Complexes 6 and 7 
follow a different synthetic route than the previous five complexes (Schemes 5 and 6). Both use a 
Buchwald-Hartwig amination, a type of C-N cross-coupling reaction, to generate the starting 
diamine (11 and 12). This is followed by a ring-closing reaction to generate the imidazolium (18) 
and pyrimidinium (19) salts required for their respective silver coordination reactions.71-73 
 
 
Scheme 5. Synthesis of 6, 11, and 18. I) Pd2(dba)3, P(t-Bu)3, NaOt-Bu, 115°, 15 hr, toluene; II) 





Scheme 6. Synthesis of 7, 12, and 19. I) Pd2(dba)3; (rac)-BINAP; NaOt-Bu, 140°, 70 hr, toluene; 
II) NH4BF4, triethyl orthoformate, 135°C, 17 hr; III) Ag2O; NMe4Cl; DCM.
73  
 
To date, only the synthesis of 11 has been attempted. A different catalyst, Pd2(dba)3, was 
used instead of the original, Pd(dba)2, as previous studies indicated no substantial differences in 
yields between the two catalysts when used in other C-N cross coupling reactions.71,74 During the 
first attempt at synthesizing 11, isolation and work-up generated a pale grey solid which matched 
the reported appearance.71 However, the solid failed to dissolve in the reported NMR solvent, 
CDCl3, as well as CD2Cl2 even after sonication. Further exploration of the literature has found that 
while the reported appearance of 11 varies widely, the compound is soluble in CDCl3, thus 
indicating 11 was not successfully made.75,76 During the second attempt, the amounts of the 
reagents were kept the same and a 250 mL Schlenk flask was used rather than a pressure tube to 
ensure that there was sufficient headspace for the reaction to properly reflux. Additionally, the 
reaction refluxed for 68.25 hr rather than 15 hr and more stringent standards regarding glovebox 
O2 levels were employed due to Buchwald-Hartwig amination’s sensitivity to air.
77 At the end of 
the second attempt’s reflux, the solution had turned dark brown/black whereas during the first 
attempt, the solution only turned light brown. Isolation and work-up yielded another pale grey 
solid, but with a higher yield when compared to the first attempt (0.28 g vs 0.09 g). Unfortunately, 
the previous NMR solvent solubility issues persisted, indicating that 11 was not made. 
To understand why the product had failed to form, 1H NMR was used to monitor the 
coupling of 2,4,6-trimethylaniline to 1,2-dicholormethane in benzene-d6. Over the course of 
308.75 hr, the reaction temperature was gradually raised from 40°C to 130°C with 1H NMRs taken 
of the sample at various time points. Spectral analysis indicated that a reaction did occur as the 
original peaks began either shifting or disappearing and new peaks began forming after 40 hrs. 
Based on spectral analysis, the reaction appeared to mostly be complete at 140 hr. While peaks 
continued to decrease in size or disappear up until the last measurement, there is a chance that that 
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could be attributed to the decomposition of the synthesized compound. Based on the results of the 
complexation studies, the 1H NMR monitoring experiment will be repeated using toluene-d6 to 
determine if the cross-coupling occurred since toluene is the solvent used in the Berke protocol.  
Given the spectral data and the fact that products were isolated, it possible that the 
Buchwald-Hartwig amination did not go to completion, resulting in only the formation of a 
monochloroaniline rather than the desired diamine. The monochloroaniline product could easily 
be identified via mass spectroscopy due to characteristic M+ and M+2 molecular ion peaks in a 
3:1 ratio. The Diver group had previously developed a similar protocol for synthesizing various 
benzimidazolium salts, using 1,2-dibromobenzene as the coupling partner, rather than 1,2-
dichlorobenzene.78 Rather than synthesizing the diamine using only one amination like the Berke 
group, the Diver group set up two subsequent cross-couplings.71,78 The first coupling yielded a 
monobromoaniline which was then isolated and purified before being used as the coupling partner 
in the next Buchwad-Hartwig reaction amination. The reaction conditions reported by the Diver 
group for the synthesis of the monoaminated products were similar enough to the conditions 
reported by the Berke group for the diaminated product. In general, the Diver reactions involved 
lower temperatures, generally ran for longer times, and used a different bulky phosphine 
(BINAP).71,78 It is possible that Diver’s tandem Buchwald-Amination process could be modified 
for the Berke protocol to successfully yield 11. 
If subsequent attempts at synthesizing 11 fail, the next step is to alter the reaction 
conditions. There is some latitude regarding what can go into the Buchwald-Hartwig reaction 
mixture, as there are numerous reported conditions for C-N cross couplings.80 In total, there are 
seven alterable variables that can impact the reaction: the starting materials, the catalyst, the base, 
the ligands, the solvent, the temperature, and the length of the reaction.79-82 As such, multiple small-
scale Buchwald-Hartwig aminations with varying reaction conditions will be run (Table 1). For 
all reactions, the ligand [P(t-Bu)3], the solvent (toluene), temperature (110°C), and length (24 hr) 
will remain the same. The most successful reaction from that series will then be scaled up to 







Table 1. Buchwald-Hartwig amination reaction matrix.  
Attempt Catalyst Base Ligand Solvent Temp (°C) Length Yield 
1 Pd2(dba)3 NaOt-Bu P(t-Bu)3 Toluene 90°C 15 hr 0% 
2 Pd2(dba)3 NaOt-Bu P(t-Bu)3 Toluene 110°C 69.75 hr 0% 
3 Pd2(dba)3 Cs2CO3 P(t-Bu)3 Toluene 110°C 24 hr TBD 
4 Pd(OAc)2 NaOt-Bu P(t-Bu)3 Toluene 110°C 24 hr TBD 
5 Pd(OAc)2 Cs2CO3 P(t-Bu)3 Toluene 110°C 24 hr TBD 
 
Conclusion 
To assess the influence of NHC sterics and electronics on bioactivity against S. mutans, a series of 
Ag(I)-NHC complexes (1-5) and their precursors were synthesized with low to moderate yields. 
Challenges arose during the syntheses of imidazolium chlorides 14 and 15 and complex 3, 
requiring multiple attempts to synthesize. For future attempts at synthesizing these compounds, 
the amount of the catalytic reagents should be increased, and the isolation and recrystallization 
protocols should be optimized in order to improve overall yields. Future work should prioritize 
completing the syntheses of [(BMes)AgCl] (6) and [(6-Mes)AgCl] (7) and generating enough of 
all the ligands and complexes for the antibacterial assays. After which, all synthesized compounds 
will be given to the Santiago lab (Rollins Dept. of Biology) where they will be screened against S. 
mutans to assess their antibacterial activity. The data that results from these studies will inform 





Experimental Methods  
General Considerations 
All complexation and coupling reactions were done under nitrogen atmosphere in an Inert Lab 
2GB Glovebox System (Innovative Technology) or on a Schlenk line. NMR spectra were obtained 
on a JEOL 300 MHz spectrometer and analyzed using Mnova (v10.0.2). Deuterated solvents were 
purchased from Cambridge Isotope Laboratories and referenced to the following chemical shifts: 
CDCl3 (
1H: δ7.26; 13C: 77.16), C6D6 (δ7.16), CD3CN (δ1.94), and CD2Cl2 (δ5.32). The DCM, 
THF, hexanes, pentane, heptane, formic acid, methanol, 2,3-butanedione, paraformaldehyde, 
chloroform, acetonitrile, sodium bicarbonate, magnesium sulfate, and 1,2-dichlorobenzene were 
purchased from Sigma Aldrich. The Ag2O, 1,3-bis(2,4,6-trimethylphenyl)imidazolinium chloride, 
1,3-bis-(2,6-diisopropylphenyl)imidazolinium chloride, Pd2(dba)3, and P(tBu)3 (10% in hexanes) 
were purchased from Strem. The glyoxal (40 wt% in H2O) and 2,6-diisopropylaniline were 
purchased from Alfa Aesar. The Celite was purchased from EMD Millipore. The 2,4,6-
trimethylaniline was purchased from Bean Town Chemical. The diethyl ether was purchased from 
Pharmco. The ethyl acetate was purchased from both Sigma Aldrich and VWR. The 4M HCl in 
dioxane and sodium t-butoxide were purchased from Oakwood Chemicals.  
 
Syntheses of Ag(I)-NHCs 
Synthesis of [1,3-bis(2,4,6-trimethylphenyl)-imidazol-2-ylidene]silver(I) chloride (1)  
Adapted from Vasam, C. S. et al. Imidazolium chloride `13 (0.467 mmol; 0.189 g) was dissolved 
in DCM (10 mL). Ag2O (0.2784 mmol; 0.0651 g) was added and the solution stirred at RT for 52 
hr. The resulting solution was filtered through Celite and removed from the glovebox. The solution 
was concentrated in vacuo and the resulting solid dissolved in minimal THF. Recrystallization 
with hexanes at 0°C and vacuum filtration yielded [1,3-bis(2,4,6-trimethylphenyl)-imidazol-2-
ylidene]silver(I) chloride (0.069 g; 41%) as a beige, lustrous powder. 1H NMR (300 MHz, CDCl3) 
δ 7.13 (d, J = 1.8 Hz, 2H), 6.99 (s, 4H), 2.35 (s, 6H), 2.07 (s, 12H).57 
 
Synthesis of [1,3-bis(2,6-diisopropylphenyl)-imidazol-2-ylidene]silver(I)  chloride (2) 
Adapted from Vasam, C. S. et al. Imidazolium chloride 14 (0.294 mmol; 0.125 g) was dissolved 
in DCM (2 mL). Ag2O (0.147 mmol; 0.0344 g) was added and the solution stirred at RT for 90.5 
hr. The resulting solution was removed from the glovebox and filtered through Celite. The solution 
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was concentrated in vacuo and the resulting solid dissolved in minimal THF. Recrystallization 
with hexanes at 0°C and vacuum filtration yielded of [1,3-bis[2,6-diisopropylphenyl)]imidazol-2-
ylidene]silver(I) chloride (0.0346 g; 22%) as a white powder. 1H NMR (300 MHz, CDCl3) δ 7.53-
7.47 (t, J = 9.0 Hz, 2H), 7.31-7.26 (m, J = 7.5 Hz, 4H), 7.21 (s, 2H), 2.58-2.49 (sept, J = 6.75 Hz, 
4H), 1.29-1.21 (dd, J = 16.5, 7.5 Hz, 24H).57 
 
Synthesis of [(1,3-bis(2,4,6-trimethylphenyl)-4,5-dimethyl-imidazol-2-ylidene]silver chloride (3)  
Imidazolium chloride 15 (0.1049 mmol; 0.0387 g) was dissolved in DCM (10 mL). Ag2O (0.1363 
mmol; 0.0316 g) was added and the solution stirred at approximately 40°C for 94.5 hr. The 
resulting solution was removed from the glovebox and filtered through Celite. The solution was 
concentrated in vacuo and the resulting solid dissolved in minimal DCM. Recrystallization with 
pentane at 0°C and vacuum filtration yielded [(1,3-bis(2,4,6-trimethylphenyl)-4,5-dimethyl-
imidazol-2-ylidene]silver chloride (0.0231 g; 46%) as a beige, sparkly powder. 1H NMR (300 
MHz, CDCl3) δ 6.98 (s, 4H), 2.34 (s, 6H), 2.00 (s, 12H), 1.90 (s, 6H). 
 
Synthesis of [1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]silver(I) chloride (4)  
Adapted from Nolan, S. P. et al. The salt, 1,3-bis(2,4,6-trimethylphenyl)imidazolinium chloride 
(16) (0.333 mmol; 0.114 g) was dissolved in DCM (10 mL). Ag2O (0.383 mmol; 0.0895 g) was 
added and the solution was refluxed for 5 hr, stirred at RT for 18.5 hr, and refluxed again for 7 hr. 
The resulting solution stirred at RT for 4 days before being removed from the glovebox and filtered 
through Celite. The solution was cooled to 0°C and recrystallized with heptane. Vacuum filtration 
and washing with pentane (10 mL) yielded of [1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-
ylidene]silver(I) chloride (0.115 g; 77%) as a sand brown, flaky solid. 1H NMR (300 MHz, CDCl3) 
δ 6.95 (s, 4H), 4.00 (s, 4H), 2.29 (s, 18H).60 
 
Synthesis of [1,3-bis[2,6-(diisopropylphenyl)]imidazolidin-2-ylidene]silver(I) chloride (5) 
Adapted from Nolan, S. P. et al. The salt, 1,3-bis-(2,6-diisopropylphenyl)imidazolinium chloride 
(17) (0.28 mmol; 0.120 g) was dissolved in DCM (10 mL). Ag2O (0.173 mmol; 0.0402 g) was 
added and the solution stirred at RT for 68.5 hr. The resulting solution was removed from the 
glovebox and filtered through Celite. The addition of pentane (30 mL) generated a precipitate that 
was washed with more pentane (3 x 10 mL). Vacuum filtration and drying under vacuum yielded 
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[1,3-bis[2,6-(diisopropylphenyl)]imidazolidin-2-ylidene]silver(I) chloride (0.0559 g; 37%) as a 
cream powder. 1H NMR (301 MHz, CDCl3) δ 7.44-7.39 (t, J = 7.5 Hz, 2H), 7.26-7.23 (cmplx, 4H), 
4.07 (s, 4H), 3.12-2.98 (sept, J = 7.1 Hz, 4H), 1.36-1.33 (dd, J = 1.62 Hz, 24H).60 
 
Syntheses of Diazabutadiene Precursors 
Synthesis of N,N'-bis(2,4,6-trimethylphenyl)-1,4-diazabutadiene (8)  
Adapted from Nolan and Bantreil. Methanol (100 mL) was used to dissolve 2,4,6-trimethylaniline 
(178.36 mmol; 25 mL). The dark blue solution stirred for 5 minutes before glyoxal (89.19 mmol; 
10.2 mL) was added, followed by formic acid (2.42 mmol %). The solution stirred at RT for 23 
hr. Vacuum filtration and washing with methanol (3 x 100 mL) yielded N,N'-bis(2,4,6-
trimethylphenyl)-1,4-diazabutadiene (18.43 g, 71%) as a neon yellow powder. 1H NMR (300 MHz, 
CDCl3) δ 8.10 (s, 2H), 6.91 (s, 1H), 2.29 (s, 6H), 2.16 (s, 12H).
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Synthesis of N,N'-bis(2,6-diisopropylphenyl)-1,4-diazabutadiene (9)  
Adapted from Nolan and Bantreil. Methanol (8 mL) was used to dissolved 2,6-diisopropylaniline 
(15.92 mmol; 3 mL). The red solution stirred for 5 minutes before glyoxal (7.97 mmol; 0.9 mL) 
was added, followed by formic acid (22.7 mmol %). The solution stirred at RT for 21 hr. Vacuum 
filtration and washing with methanol (3 x 15 mL) yielded N,N'-bis(2,6-diisopropylphenyl)-1,4-
diazabutadiene (1.92 g, 64%) as a neon yellow powder. 1H NMR (300 MHz, CDCl3) δ 8.10 (s, 
2H), 7.22-7.16 (m, J = 4.5 Hz, 6H), 3.01-2.87 (sept, J = 6.8 Hz, 4H), 1.21 (d, J = 6.9 Hz, 24H).55 
 
Synthesis of N,N'-bis(2,4,6-trimethylphenyl)butane-2,3-diimine (10)  
Adapted from Lamaty, Métro, Bantreil, et al. Methanol (240 mL) was used to dissolved 2,4,6-
trimethylaniline (237.2 2 mmol; 33 mL). The dark blue solution was cooled to 0°C before 2,3-
butanedione (118.6 mmol; 10.3 mL) was added, followed by formic acid (9.7 mmol %). The 
solution stirred at RT for 48 hr. Vacuum filtration and washing with methanol (2 x 100 mL) and 
diethyl ether (2 x 100 mL) yielded N,N'-bis(2,4,6-trimethylphenyl)butane-2,3-diimine (21.78 g, 
57%) as a neon yellow powder. 1H NMR (300 MHz, CDCl3) δ 6.89 (s, 4H), 2.29 (s, 6H), 2.03 (s 





Syntheses of Imidazolium Chlorides 
Synthesis of 1,3-bis-(2,4,6-trimethylphenyl)imidazolium chloride (13)  
Adapted from Nolan, S. P. and Bantreil, X. Compound 8 (17.10 mmol; 5 g) was dissolved in ethyl 
acetate (35 mL) while paraformaldehyde (18.59 mmol; 0.558 g) was dissolved in 4 M HCl in 
dioxane (25.65 mmol; 6.41 mL). The paraformaldehyde-HCl solution was added dropwise to the 
ethyl acetate solution. After gently heating for 1 hr, the reaction mixture stirred at RT for 17 hr. 
Vacuum filtration, washing with ethyl acetate (3 x 50 mL), and drying under vacuum yielded 1,3-
bis-(2,4,6-trimethylphenyl)imidazolium chloride (5.247 g, 90%) as an off-white powder. 1H NMR 
(300 MHz, CDCl3) δ 10.91 (s, 1H), 7.61 (s, 2H), 7.01 (s, 4H), 2.33 (s, 6H), 2.17 (s, 12 H).
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Synthesis of 1,3-bis-(2,6-diisopropylphenyl)imidazolinium chloride (14)  
Adapted from Jones, W. et al. Compound 9 (13.27 mmol; 5 g) was dissolved in ethyl acetate (30 
mL) while paraformaldehyde (14.59 mmol; 0.4381 g) was dissolved in 4 M HCl in dioxane  
(19.90 mmol; 5 mL). The paraformaldehyde-HCl solution was added dropwise to the ethyl acetate 
solution and the reaction mixture stirred at RT for 20 hr. The precipitate was vacuum filtered and 
washed with ethyl acetate before being dissolved in chloroform. Concentrating in vacuo and drying 
under vacuum yielded 1,3-bis-(2,6-diisopropylphenyl)imidazolinium chloride (3.94 g, 70%) as a 
light brown powder. 1H NMR (300 MHz, CDCl3) δ 10.05 (s, 1H), 8.15 (s, 2H), 7.57 (t, J = 7.9 Hz, 
2H), 7.34 (d, J = 7.8 Hz, 4H), 2.46-2.43 (m, J = 4.5 Hz, 4H), 1.30-1.23 (dd, J = 15.0, 6.0 Hz, 
24H).56 
 
Synthesis of [1,3-bis(2,4,6-trimethylphenyl)-4,5-methyl]imidazolium chloride (15)  
Adapted from Louie, J. et al. and Lamaty, F. et al. Compound 10 (23.3 mmol; 9.44 g) was dissolved 
in ethyl acetate (400 mL) cooled to 0°C. Paraformaldehyde (30.3 mmol; 1.02 g) and 4 M HCl in 
dioxane (37.3 mmol; 9.3 mL) were dissolved in ethyl acetate (100 mL). After being placed in an 
ice bath for 10 min, the paraformaldehyde-HCl solution was added to the 10 solution and the 
mixture stirred at RT for 19.75 hr. The resulting terracotta precipitate was vacuum filtered and 
washed with diethyl ether (2.5 L). Precipitate was stored in diethyl ether (100 mL) and stirred for 
18 days. Light brown solid was vacuum filtered and dissolved in methanol (50 mL) and acetonitrile 
(50 mL). The solution was stirred with NaHCO3 for 30 min before being filtered and concentrated 
in vacuo. The resulting oily residue was triturated with pentane (8 x 15 mL), yielding both brown 
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granules and solids. Granules were discarded while the solids were dried via rotary evaporation. 
The resulting light brown powder was dissolved in saturated NaHCO3
 and washed with ethyl 
acetate (4 x 100 mL). Extraction with DCM (3 x 100 mL), drying with MgSO4, and concentration 
in vacuo yielded [1,3-bis(2,4,6-trimethylphenyl)-4,5-methyl]imidazolium chloride (1.3591 g; 
16%) as a beige flaky powder. 1H NMR (300 MHz, CDCl3) δ 10.82 (s, 1H), 7.03 (s, 4H), 2.34 (s, 
6H), 2.12 (s, 12H), 2.06 (s, 6H). 1H NMR (300 MHz, CD3CN) δ 8.90 (s, 1H), 7.15 (s, 4H), 2.35 
(s, 6H), 2.04 (s, 12H), 2.00 (cmplx, 6H).58,59 
 
1H NMR Reaction Monitoring Studies  
Monitoring the Complexation of 15 to Silver(I) 
Imidazolium chloride 15 (0.040657 mmol; 0.015 g) and Ag2O (0.05285 mmol; 0.01225 g) were 
dissolved CD2Cl2 (~0.5 mL) in a J. Young tube. The tube was taken out of the glovebox and an 
initial NMR was taken before being placed in a 40°C oil bath for 14.75 hours after which another 
NMR was taken. The oil bath temperature was raised to 50°C before placing the J. Young back in. 
NMRs were taken at 24 hr intervals for the next three days.   
 
Monitoring the Cross-Coupling of 2,4,6-trimethylaniline to 1,2-dicholormethane in benzene-d6 
Adapted from Berke, H. et al. Under nitrogen, a round bottom flask was charged with Pd2(dba)3 
(0.01 mmol; 0.00915 g), followed by P(tBu)3 (0.022 mmol; 0.07 mL) and C6D6 (5 mL) and stirred 
at RT for 10 min. The flask was then charged with 1,2-dichlorobenzene (1.43 mmol; 0.161 mL), 
2,4,6-trimethylaniline (4.08 mmol; 0.573 mL), NaOtBu (4.09 mmol, 0.393 g), and additional C6D6 
(5 mL). An aliquot (~0.5 mL) was taken and placed in a J. Young tube. The tube was taken out of 
the glovebox and an initial NMR was taken before being placed in a 40°C oil bath for 15 hr after 
which another NMR was taken. The oil bath temperature was raised to 70°C before placing the J. 
Young back in. An NMR was taken 25 hr later after which the bath temperature was raised to 
100°C and then returned to RT. An additional NMR was taken at t=140.75 hr before the bath 
temperature was raised to 115°C. NMRs were taken 24 and 43 hrs later. The oil bath temperature 
was raised to 130°C before and an NMR was taken 24 hr later. J. Young was cooled to RT and a 
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